CU23178A1 - INMUNOTERAPIA ACTIVA ANTIANGIOGéNICA - Google Patents
INMUNOTERAPIA ACTIVA ANTIANGIOGéNICAInfo
- Publication number
- CU23178A1 CU23178A1 CU20020076A CU20020076A CU23178A1 CU 23178 A1 CU23178 A1 CU 23178A1 CU 20020076 A CU20020076 A CU 20020076A CU 20020076 A CU20020076 A CU 20020076A CU 23178 A1 CU23178 A1 CU 23178A1
- Authority
- CU
- Cuba
- Prior art keywords
- active
- receptors
- antiangiogen
- immunotherapy
- active immunotherapy
- Prior art date
Links
- 238000009169 immunotherapy Methods 0.000 title abstract 2
- 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 abstract 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 abstract 2
- 208000003120 Angiofibroma Diseases 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 208000010412 Glaucoma Diseases 0.000 abstract 1
- 206010027476 Metastases Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 108091034117 Oligonucleotide Proteins 0.000 abstract 1
- 208000017442 Retinal disease Diseases 0.000 abstract 1
- 206010038923 Retinopathy Diseases 0.000 abstract 1
- 206010052779 Transplant rejections Diseases 0.000 abstract 1
- 230000008578 acute process Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000006020 chronic inflammation Effects 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 201000011066 hemangioma Diseases 0.000 abstract 1
- 208000002780 macular degeneration Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000012986 modification Methods 0.000 abstract 1
- 230000004048 modification Effects 0.000 abstract 1
- 201000003142 neovascular glaucoma Diseases 0.000 abstract 1
- 210000000056 organ Anatomy 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 210000005166 vasculature Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
- A61K38/1866—Vascular endothelial growth factor [VEGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001109—Vascular endothelial growth factor receptors [VEGFR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00113—Growth factors
- A61K39/001135—Vascular endothelial growth factor [VEGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/515—Angiogenesic factors; Angiogenin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55588—Adjuvants of undefined constitution
- A61K2039/55594—Adjuvants of undefined constitution from bacteria
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Vascular Medicine (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Rheumatology (AREA)
- Biotechnology (AREA)
- Transplantation (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
Abstract
Aplicacion de secuencias oligonucleotídicas y polipÉotidas de molÉculas pertenecientes a la familia del factor de permeabilidad vascular (VPF), sus receptores y correceptores; así como modificaciones de los mismos, en la inmunoterapia activa de entidades patologicas cuyo curso se asocia al aumento de la vasculatura. Estos procedimientos pueden ser empleados en la terpaia Unica o combinada para el tratamiento del cAncer y sus metAstasis, los procesos inflamatorios agudos y cronicos, enfermedades infecciosas, enfermedades autoinmunes, la retinopatía diabÉtica y del reciÉn nacido, el rechazo a trasplante de organos, la degeneracion macular, los glaucomas neovasculares, hemangiomas y los angiofibromas, entre otros.
Priority Applications (19)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CU20020076A CU23178A1 (es) | 2002-04-15 | 2002-04-15 | INMUNOTERAPIA ACTIVA ANTIANGIOGéNICA |
ARP030101264A AR039285A1 (es) | 2002-04-15 | 2003-04-10 | Inmunoterapia activa antiangiogenica composicion vacunal |
ES03711811T ES2365329T3 (es) | 2002-04-15 | 2003-04-11 | Uso de vegf mutado para la terapia antiangiogenica. |
PCT/CU2003/000004 WO2003086450A1 (es) | 2002-04-15 | 2003-04-11 | Inmunoterapia activa antiangiogenica. |
US10/511,384 US7556809B2 (en) | 2002-04-15 | 2003-04-11 | Active antiangiogenic therapy |
AU2003218603A AU2003218603B2 (en) | 2002-04-15 | 2003-04-11 | Active antiangiogenic therapy |
PT03711811T PT1502599E (pt) | 2002-04-15 | 2003-04-11 | Terapia anti-angiogénica activa |
DK03711811.4T DK1502599T3 (da) | 2002-04-15 | 2003-04-11 | Anvendelse af muteret VEGF til antiangiogen terapi |
KR1020047016584A KR100704127B1 (ko) | 2002-04-15 | 2003-04-11 | 혈관형성억제 활성 면역치료 |
EP03711811A EP1502599B1 (en) | 2002-04-15 | 2003-04-11 | Use of mutated VEGF for antiangiogenic therapy |
CN03808567.4A CN1646153B (zh) | 2002-04-15 | 2003-04-11 | 抗血管生成的主动免疫疗法 |
SI200332037T SI1502599T1 (sl) | 2002-04-15 | 2003-04-11 | Uporaba mutiranega VEGF za antiangiogenetsko terapijo |
JP2003583468A JP4741800B2 (ja) | 2002-04-15 | 2003-04-11 | 抗血管新生活性療法 |
CA2480079A CA2480079C (en) | 2002-04-15 | 2003-04-11 | Antiangiogenic active immunotherapy |
AT03711811T ATE511851T1 (de) | 2002-04-15 | 2003-04-11 | Verwendung eines vgefmutants zur antiangiogene therapie |
RU2004133338/15A RU2329824C2 (ru) | 2002-04-15 | 2003-04-11 | Активная иммунотерапия против ангиогенеза |
ZA200408460A ZA200408460B (en) | 2002-04-15 | 2004-10-19 | Active antiangiogenic therapy. |
US11/787,522 US20080254050A1 (en) | 2002-04-15 | 2007-04-17 | Antiangiogenic active immunotherapy |
US12/612,455 US8883724B2 (en) | 2002-04-15 | 2009-11-04 | Active antiangiogenic therapy |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CU20020076A CU23178A1 (es) | 2002-04-15 | 2002-04-15 | INMUNOTERAPIA ACTIVA ANTIANGIOGéNICA |
Publications (1)
Publication Number | Publication Date |
---|---|
CU23178A1 true CU23178A1 (es) | 2006-09-22 |
Family
ID=40134850
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CU20020076A CU23178A1 (es) | 2002-04-15 | 2002-04-15 | INMUNOTERAPIA ACTIVA ANTIANGIOGéNICA |
Country Status (17)
Country | Link |
---|---|
US (3) | US7556809B2 (es) |
EP (1) | EP1502599B1 (es) |
JP (1) | JP4741800B2 (es) |
KR (1) | KR100704127B1 (es) |
CN (1) | CN1646153B (es) |
AR (1) | AR039285A1 (es) |
AT (1) | ATE511851T1 (es) |
AU (1) | AU2003218603B2 (es) |
CA (1) | CA2480079C (es) |
CU (1) | CU23178A1 (es) |
DK (1) | DK1502599T3 (es) |
ES (1) | ES2365329T3 (es) |
PT (1) | PT1502599E (es) |
RU (1) | RU2329824C2 (es) |
SI (1) | SI1502599T1 (es) |
WO (1) | WO2003086450A1 (es) |
ZA (1) | ZA200408460B (es) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CU23178A1 (es) * | 2002-04-15 | 2006-09-22 | Ct Ingenieria Genetica Biotech | INMUNOTERAPIA ACTIVA ANTIANGIOGéNICA |
DK1548032T3 (da) | 2002-09-12 | 2009-08-17 | Oncotherapy Science Inc | KDR-peptider og vacciner indeholdende disse |
CN101094688B (zh) | 2004-09-13 | 2013-05-01 | 建新公司 | 多聚构建体 |
WO2006093030A1 (en) | 2005-02-28 | 2006-09-08 | Oncotherapy Science, Inc. | Epitope peptides derived from vascular endothelial growth factor receptor 1 and vaccines containing these peptides |
US20060234941A1 (en) * | 2005-04-15 | 2006-10-19 | The Gov. Of The Usa As Represented By The Secretary Of The Dept. Of Health & Human Services | Peptide epitopes of VEGFR-2/KDR that inhibit angiogenesis |
EP2272497B1 (en) | 2006-01-18 | 2012-10-03 | The General Hospital Corporation | Methods of increasing lymphatic function |
CN101394857A (zh) * | 2006-02-01 | 2009-03-25 | 爱吉恩公司 | 含有寡聚核苷酸和无毒lps的用于治疗癌症的组合物 |
US20100297157A1 (en) * | 2007-02-16 | 2010-11-25 | Yasuhiro Tamaki | Vaccine therapy for choroidal neovascularization |
AU2008296733B2 (en) * | 2007-08-08 | 2013-07-11 | The Board Of Regents Of The University Of Texas System | VEGFR-1/NRP-1 targeting peptides |
TWI436775B (zh) * | 2007-08-24 | 2014-05-11 | Oncotherapy Science Inc | 以抗原胜肽合併化療藥劑治療胰臟癌 |
KR20110008261A (ko) * | 2008-04-24 | 2011-01-26 | 쓰리엠 이노베이티브 프로퍼티즈 컴파니 | 웨이블릿 변환을 사용한 핵산 증폭 곡선의 분석 |
EP2358877A2 (en) * | 2008-11-21 | 2011-08-24 | Reliance Life Sciences Pvt., Ltd. | Inhibition of vegf-a secretion, angiogenesis and/or neoangiogenesis by sina mediated knockdown of vegf-c and rhoa |
JP5539411B2 (ja) | 2009-03-04 | 2014-07-02 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 血管新生因子を含む組成物およびその使用方法 |
TW201109029A (en) * | 2009-06-11 | 2011-03-16 | Oncotherapy Science Inc | Vaccine therapy for choroidal neovascularization |
WO2012019128A1 (en) | 2010-08-06 | 2012-02-09 | Genzyme Corporation | Vegf antagonist compositions and uses thereof |
RU2444378C1 (ru) * | 2010-09-06 | 2012-03-10 | Олег Германович Макеев | Способ лечения коронарной недостаточности при моделируемой ишемии миокарда |
WO2012088563A1 (en) * | 2010-11-24 | 2012-07-05 | Vegenics Pty Limited | Vegfr-2-specific forms of vegf-d and vegf-c and uses thereof |
US9345770B2 (en) * | 2011-11-16 | 2016-05-24 | University of Pittsburgh—of the Commonwealth System of Higher Education | Immunogenic tumor associated stromal cell antigen peptides and methods of their use |
US10543261B2 (en) | 2012-08-31 | 2020-01-28 | Osaka University | DNA vaccine containing VEGF-specific epitope and/or angiopoietin-2-specific epitope |
EP3096769A1 (en) * | 2014-01-21 | 2016-11-30 | University of Helsinki | Therapeutic use of vegfr-3 ligands |
KR101509047B1 (ko) * | 2014-07-28 | 2015-04-08 | 한국생명공학연구원 | Neuropilin 1 유전자를 이용한 천식 진단 및 천식 치료제 스크리닝 방법 |
EP3402815B1 (en) | 2016-01-15 | 2023-12-06 | University of Maryland, College Park | Endo-s2 mutants as glycosynthases, method of making and use for glycoengineering of glycoproteins |
CA3029752C (en) * | 2016-07-05 | 2022-03-15 | Ibentrus, Inc. | Cancer treatment composition for inhibiting tumor angiogenesis, containing vegf deep blocker, and preparation method therefor |
CN109715819A (zh) | 2016-08-10 | 2019-05-03 | 马里兰大学帕克分校 | 设计者α1,6-岩藻糖苷酶突变体实现完整N-糖肽和N-糖蛋白的直接核心岩藻糖基化 |
US20200147194A1 (en) * | 2017-05-19 | 2020-05-14 | Keio University | Peptide vaccine and peptide vaccine composition for cranial nerve disease |
US11459380B2 (en) | 2017-06-29 | 2022-10-04 | University Of Maryland, College Park | Transglycosylation of endo-S and endo-S mutants for antibody glycosylation remodeling |
CN111487398B (zh) * | 2019-01-25 | 2022-11-11 | 四川大学华西医院 | 血管瘤治疗的生物标记物 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5219739A (en) * | 1989-07-27 | 1993-06-15 | Scios Nova Inc. | DNA sequences encoding bVEGF120 and hVEGF121 and methods for the production of bovine and human vascular endothelial cell growth factors, bVEGF120 and hVEGF121 |
PT694042E (pt) * | 1993-03-25 | 2005-02-28 | Merck & Co Inc | Inibidor do factor de crescimento de celulas endoteliais vasculares |
US6149921A (en) * | 1993-12-29 | 2000-11-21 | Centro De Inmunologia Molecular | Vaccine compositions for eliciting an immune response against N-acetylated gangliosides and their use for cancer treatment |
WO1996006641A1 (en) * | 1994-08-29 | 1996-03-07 | Prizm Pharmaceuticals, Inc. | Conjugates of vascular endothelial growth factor with targeted agents |
WO1999045018A1 (en) * | 1998-03-06 | 1999-09-10 | Imclone Systems Incorporated | Active immunization against angiogenesis-associated antigens |
WO1999057981A1 (en) * | 1998-05-08 | 1999-11-18 | Sloan-Kettering Institute For Cancer Research | Compositions and methods for active vaccination |
KR20010102556A (ko) | 1999-03-11 | 2001-11-15 | 추후제출 | 암 및 과증식성 장애의 치료 조성물 및 치료방법 |
EP1252177A1 (en) * | 2000-02-04 | 2002-10-30 | Supratek Pharma, Inc. | Ligand for vascular endothelial growth factor receptor |
US7094410B2 (en) * | 2002-03-02 | 2006-08-22 | The Scripps Research Institute | DNA vaccine against proliferating endothelial cells and methods of use thereof |
CU23178A1 (es) * | 2002-04-15 | 2006-09-22 | Ct Ingenieria Genetica Biotech | INMUNOTERAPIA ACTIVA ANTIANGIOGéNICA |
-
2002
- 2002-04-15 CU CU20020076A patent/CU23178A1/es unknown
-
2003
- 2003-04-10 AR ARP030101264A patent/AR039285A1/es unknown
- 2003-04-11 CN CN03808567.4A patent/CN1646153B/zh not_active Expired - Lifetime
- 2003-04-11 PT PT03711811T patent/PT1502599E/pt unknown
- 2003-04-11 AT AT03711811T patent/ATE511851T1/de active
- 2003-04-11 CA CA2480079A patent/CA2480079C/en not_active Expired - Lifetime
- 2003-04-11 SI SI200332037T patent/SI1502599T1/sl unknown
- 2003-04-11 RU RU2004133338/15A patent/RU2329824C2/ru active IP Right Revival
- 2003-04-11 KR KR1020047016584A patent/KR100704127B1/ko active IP Right Grant
- 2003-04-11 DK DK03711811.4T patent/DK1502599T3/da active
- 2003-04-11 JP JP2003583468A patent/JP4741800B2/ja not_active Expired - Fee Related
- 2003-04-11 US US10/511,384 patent/US7556809B2/en not_active Expired - Lifetime
- 2003-04-11 ES ES03711811T patent/ES2365329T3/es not_active Expired - Lifetime
- 2003-04-11 AU AU2003218603A patent/AU2003218603B2/en not_active Ceased
- 2003-04-11 WO PCT/CU2003/000004 patent/WO2003086450A1/es active Application Filing
- 2003-04-11 EP EP03711811A patent/EP1502599B1/en not_active Expired - Lifetime
-
2004
- 2004-10-19 ZA ZA200408460A patent/ZA200408460B/xx unknown
-
2007
- 2007-04-17 US US11/787,522 patent/US20080254050A1/en not_active Abandoned
-
2009
- 2009-11-04 US US12/612,455 patent/US8883724B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
JP2006501145A (ja) | 2006-01-12 |
US20100047265A1 (en) | 2010-02-25 |
RU2004133338A (ru) | 2005-06-10 |
AU2003218603A1 (en) | 2003-10-27 |
EP1502599B1 (en) | 2011-06-08 |
DK1502599T3 (da) | 2011-08-01 |
JP4741800B2 (ja) | 2011-08-10 |
ES2365329T3 (es) | 2011-09-29 |
EP1502599A1 (en) | 2005-02-02 |
US20050175624A1 (en) | 2005-08-11 |
ATE511851T1 (de) | 2011-06-15 |
AR039285A1 (es) | 2005-02-16 |
CN1646153A (zh) | 2005-07-27 |
SI1502599T1 (sl) | 2011-10-28 |
KR100704127B1 (ko) | 2007-04-05 |
US20080254050A1 (en) | 2008-10-16 |
RU2329824C2 (ru) | 2008-07-27 |
US8883724B2 (en) | 2014-11-11 |
ZA200408460B (en) | 2005-08-30 |
PT1502599E (pt) | 2011-08-03 |
CA2480079C (en) | 2013-07-30 |
AU2003218603B2 (en) | 2009-05-28 |
WO2003086450A1 (es) | 2003-10-23 |
CN1646153B (zh) | 2017-05-24 |
CA2480079A1 (en) | 2003-10-23 |
KR20040111526A (ko) | 2004-12-31 |
US7556809B2 (en) | 2009-07-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CU23178A1 (es) | INMUNOTERAPIA ACTIVA ANTIANGIOGéNICA | |
van den Boorn et al. | Inflammasome-dependent induction of adaptive NK cell memory | |
Ziani et al. | Alteration of the antitumor immune response by cancer-associated fibroblasts | |
JP6779931B2 (ja) | 肺疾患及び肺障害の炎症促進性メディエータのhUTC調節 | |
Von Luttichau et al. | Human adult CD34-progenitor cells functionally express the chemokine receptors CCR1, CCR4, CCR7, CXCR5, and CCR10 but not CXCR4 | |
Rao et al. | Enhanced enrichment of prostate cancer stem-like cells with miniaturized 3D culture in liquid core-hydrogel shell microcapsules | |
Zhu et al. | Upregulation of autophagy by hypoxia-inducible factor-1α promotes EMT and metastatic ability of CD133+ pancreatic cancer stem-like cells during intermittent hypoxia | |
Mizrak et al. | CD133: molecule of the moment | |
ES2621847T3 (es) | Células posparto derivadas de tejido de cordón umbilical, y métodos de elaboración y uso de las mismas | |
ES2600555T3 (es) | Reparación y regeneración de tejido ocular usando células derivadas del post parto | |
CA2747727C (en) | Conditioned medium and methods of making the same | |
AR078346A1 (es) | Anticuerpos humanos de alta afinidad contra el receptor activado por proteasa de tipo 2 humano | |
AR063760A1 (es) | Anticuerpos anti-factor d humanizados y usos de los mismos | |
Barth et al. | CD34+ fibrocytes: morphology, histogenesis and function | |
CR20120086A (es) | Anticuerpos humanos de alta afinidad para la angiopoyetina-2 humana | |
CO6741179A2 (es) | Mutantes fc de anticuerpos resistentes a proteasas activas | |
Zhang et al. | Hypoxia specific SDF-1 expression by retinal pigment epithelium initiates bone marrow-derived cells to participate in Choroidal neovascularization in a laser-induced mouse model | |
ATE478893T1 (de) | Genetisch hergestellte zellen für therapeutische anwendungen | |
JP2012512911A (ja) | 肺ならびに肺の疾患および障害の治療 | |
AR063448A1 (es) | Anticuerpos recombinantes contra el factor de crecimiento del endotelio vascular (vegf) | |
ATE494360T1 (de) | Neue zellpopulationen und deren anwendungen | |
ECSP20082338A (es) | Receptores del factor de crecimiento quimérico | |
Zi et al. | Fibroblast activation protein protects bortezomib-induced apoptosis in multiple myeloma cells through β-catenin signaling pathway | |
TW201932126A (zh) | 抑制血管生成之方法 | |
Kauppinen et al. | Potential role of myeloid-derived suppressor cells (MDSCs) in age-related macular degeneration (AMD) |